Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rigosertib in HMA-refractory MDS
NCT01928537Phase 3Completed
- Sponsor
- Traws Pharma, Inc.
- Start
- Aug 2013
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, open-label, single-arm trial of rigosertib in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML), sponsored by Traws Pharma, Inc. Primary endpoint: Relationship of bone marrow blast response and overall survival up to 2 years. Started Aug 2013; status: completed.
02
Drugs
rigosertib
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT01928537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01928537.